<DOC>
	<DOCNO>NCT01148758</DOCNO>
	<brief_summary>This exploratory , open label study ass dose-effect relationship , efficacy safety RO5323441 patient metastatic treatment-refractory colorectal ovarian cancer . Cohorts patient receive dos intravenous RO5323441 range 25mg 3g every 1 2 week undergo serial dynamic contrast-enhanced magnetic resonance imaging ( DCE-MRI ) assessment . In absence disease progression unacceptable toxicity , patient may continue receive maximum dose RO5323441 core treatment phase total 6 month . Treatment RO5323441 extend investigator 's discretion disease progression unacceptable toxicity occur . Target sample size &lt; 100 .</brief_summary>
	<brief_title>A Dose-finding Study RO5323441 Patients With Metastatic Treatment-Refractory Colorectal Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>adult patient , &gt; /=19 year age metastatic unresectable colorectal ovarian cancer refractory , unsuitable standard therapy presence tumor lesion suitable DCEMRI evaluation WHO performance status 01 adequate bone marrow , liver renal function patient unsuitable MRI scanning ( e.g . metal implant , pacemaker , claustrophobia , hypersensitivity DCEMRI contrast material ) brain metastasis clinically significant ascites active bleeding , bleed diathesis , oral antivitamin K medication ( low dose coumarin ) history coagulation disorder radiation therapy within 3 week , antineoplastic therapy &lt; 30 day prior first dose study drug chronic therapy systemic steroid another immunosuppressive agent &lt; 2 week prior first dose study drug treat bevacizumab last regimen systemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>